TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Livzon Pharmaceutical Group ( (HK:1513) ) has shared an update.
Livzon Pharmaceutical Group Inc. has proposed the election of Ms. Wang Zhiyao as an independent non-executive director to replace retiring directors Mr. Tian Qiusheng and Mr. Wong Kam Wa. Ms. Wang’s appointment is pending approval at the 2025 extraordinary general meeting and is expected to bring her extensive experience in the pharmaceutical and biotechnology sectors to the company, potentially enhancing its strategic direction and governance.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and sale of pharmaceutical products. The company is known for its comprehensive range of healthcare solutions and aims to maintain a strong market presence in the pharmaceutical sector.
YTD Price Performance: 20.79%
Average Trading Volume: 1,341,695
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.3B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.